Stock listing
Frankfurt:T3X Telix Pharmaceuticals Limited Aktie
German listing (Frankfurt) of Telix Pharmaceuticals Limited · home listing ASX:TLX
Follow Telix Pharmaceuticals Limited into a list and get an email when it puts out news.
Share price · FWB:T3X
€7.56 EUR -0.37 (-4.6%)
Close on Nov 20, 2026
- Day range
- €7.56 – €7.72 EURNov 20, 2026
- Market cap
- €2.57B EURAt the close on Nov 20, 2026 · price × 339.8M shares outstanding
- Traded on an average day
- €13,316 EURMedian day 400 shares · 20 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:TLX · Home | $12.92 AUD | -0.29 (-2.2%) | 1,477,613 | $13.25 | $13.25 | $12.73 | $13.21 | Close on Nov 20, 2026 |
| NASDAQ:TLX | $8.37 USD | -0.34 (-3.9%) | 269,405 | $8.66 | $8.70 | $8.365 | $8.71 | Close on Nov 20, 2026 |
| OTC:TLPPF | $8.66 USD | -0.35 (-3.9%) | 3,292 | $8.61 | $8.66 | $8.61 | $9.01 | Close on Nov 18, 2026 |
| Frankfurt:T3X | €7.556 EUR | -0.366 (-4.6%) | — | €7.713 | €7.717 | €7.556 | €7.922 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:T3X · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €8.277 | -0.475 | -5.4% | €8.289 | €8.295 | €8.277 | 0 | |
| €8.752 | +0.642 | +7.9% | €8.744 | €8.78 | €8.741 | 7,576 | |
| €8.11 | +0.134 | +1.7% | €8.139 | €8.187 | €8.11 | 7,576 | |
| €7.976 | -0.119 | -1.5% | €8.197 | €8.202 | €7.947 | 2,240 | |
| €8.095 | +0.01 | +0.1% | €8.136 | €8.153 | €8.005 | 0 | |
| €8.085 | -0.402 | -4.7% | €8.10 | €8.104 | €8.078 | 6,606 | |
| €8.487 | +0.299 | +3.7% | €8.431 | €8.691 | €8.369 | 2,250 | |
| €8.188 | +0.269 | +3.4% | €8.178 | €8.277 | €8.175 | 774 | |
| €7.919 | -0.044 | -0.6% | €7.959 | €7.992 | €7.839 | 0 | |
| €7.963 | -0.172 | -2.1% | €7.963 | €7.963 | €7.963 | 742 | |
| €8.135 | -0.384 | -4.5% | €8.158 | €8.192 | €8.108 | 0 | |
| €8.519 | -0.462 | -5.1% | €8.521 | €8.523 | €8.514 | 0 | |
| €8.981 | -0.614 | -6.4% | €9.015 | €9.315 | €8.98 | 8,000 | |
| €9.595 | -0.126 | -1.3% | €9.998 | €10.00 | €9.519 | 1,000 | |
| €9.721 | -0.006 | -0.1% | €9.67 | €9.768 | €9.636 | 0 | |
| €9.727 | +0.315 | +3.3% | €9.966 | €9.97 | €9.689 | 0 | |
| €9.412 | -0.226 | -2.3% | €9.48 | €9.583 | €9.405 | 560 | |
| €9.638 | -0.323 | -3.2% | €9.704 | €9.734 | €9.589 | 340 | |
| €9.961 | -0.136 | -1.3% | €9.793 | €10.07 | €9.701 | 1,052 | |
| €10.10 | +0.419 | +4.3% | €10.21 | €10.28 | €10.02 | 3,000 | |
| €9.678 | -0.051 | -0.5% | €9.645 | €9.68 | €9.613 | 1,200 | |
| €9.729 | -0.213 | -2.1% | €9.675 | €9.882 | €9.623 | 2,000 | |
| €9.942 | +0.257 | +2.7% | €9.942 | €10.04 | €9.94 | 3,600 | |
| €9.685 | +0.006 | +0.1% | €9.678 | €9.685 | €9.618 | 1,000 | |
| €9.679 | +0.225 | +2.4% | €9.787 | €9.916 | €9.588 | 5,700 | |
| €9.454 | -0.185 | -1.9% | €9.359 | €9.493 | €9.208 | 1,670 | |
| €9.639 | +0.018 | +0.2% | €9.686 | €9.812 | €9.569 | 0 | |
| €9.621 | -0.153 | -1.6% | €9.627 | €9.628 | €9.621 | 200 | |
| €9.774 | +0.047 | +0.5% | €9.772 | €9.797 | €9.715 | 10 | |
| €9.727 | +0.008 | +0.1% | €9.732 | €9.735 | €9.725 | 0 | |
| €9.719 | -0.207 | -2.1% | €9.719 | €9.719 | €9.719 | 204 | |
| €9.926 | -0.123 | -1.2% | €9.672 | €9.942 | €9.661 | 260 | |
| €10.05 | -0.794 | -7.3% | €9.872 | €10.08 | €9.805 | 2,000 | |
| €10.84 | +0.812 | +8.1% | €10.38 | €10.95 | €10.29 | 1,080 | |
| €10.03 | -1.245 | -11.0% | €10.06 | €10.06 | €9.92 | 5,096 | |
| €11.28 | +0.692 | +6.5% | €10.97 | €11.46 | €10.97 | 420 | |
| €10.58 | +0.262 | +2.5% | €10.59 | €10.60 | €10.58 | 0 | |
| €10.32 | -0.372 | -3.5% | €10.32 | €10.32 | €10.32 | 400 | |
| €10.69 | -0.109 | -1.0% | €10.69 | €10.69 | €10.69 | 0 | |
| €10.80 | +1.154 | +12.0% | €10.28 | €10.85 | €10.01 | 4,900 | |
| €9.649 | -0.631 | -6.1% | €9.637 | €9.674 | €9.627 | 90 | |
| €10.28 | +0.023 | +0.2% | €10.34 | €10.46 | €10.15 | 198 | |
| €10.26 | +0.294 | +3.0% | €10.28 | €10.28 | €10.24 | 0 | |
| €9.963 | -0.122 | -1.2% | €9.994 | €9.999 | €9.928 | 0 | |
| €10.09 | -0.073 | -0.7% | €10.09 | €10.17 | €10.00 | 500 | |
| €10.16 | -0.07 | -0.7% | €10.15 | €10.17 | €10.04 | 1,206 | |
| €10.23 | +0.674 | +7.1% | €10.24 | €10.29 | €10.22 | 490 | |
| €9.554 | +0.204 | +2.2% | €9.525 | €9.627 | €9.515 | 0 | |
| €9.35 | +0.002 | 0.0% | €9.369 | €9.375 | €9.35 | 0 | |
| €9.348 | -0.222 | -2.3% | €9.357 | €9.358 | €9.342 | 0 | |
| €9.57 | +0.115 | +1.2% | €9.574 | €9.597 | €9.46 | 100 | |
| €9.455 | +0.13 | +1.4% | €9.462 | €9.469 | €9.452 | 0 | |
| €9.325 | -0.363 | -3.7% | €9.33 | €9.335 | €9.314 | 0 | |
| €9.688 | -0.096 | -1.0% | €9.688 | €9.688 | €9.688 | 3,680 | |
| €9.784 | -0.727 | -6.9% | €9.784 | €9.784 | €9.784 | 0 | |
| €10.51 | +0.082 | +0.8% | €10.51 | €10.51 | €10.51 | 0 | |
| €10.43 | +0.539 | +5.4% | €10.40 | €10.67 | €10.38 | 3,570 |
- Ticker
- Frankfurt:T3X
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 3, 2026
Telix Capital Markets Day Presentation November 2026
Latest earnings call · Aug 20, 2026
Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Investor Day (November 2026)
Investor day · 94 slides
Latest news
Appendix 3Y Maria Rivas
Nov 4, 2026
Closed €8.75 (+7.9%) on Nov 5, 2026
Telix Capital Markets Day Presentation November 2026
Nov 3, 2026
Closed €8.11 (+1.7%) on Nov 4, 2026
Change of Director's Interest Notice - Marie McDonald
Nov 3, 2026
Closed €7.98 (-1.5%) on Nov 3, 2026
Notification regarding unquoted securities - TLX
Nov 3, 2026
Closed €7.98 (-1.5%) on Nov 3, 2026
Cancellation of Appendix 2A
Nov 2, 2026
Closed €7.98 (-1.5%) on Nov 3, 2026
Notice of General Meeting
Oct 29, 2026
Closed €8.09 (-4.7%) on Oct 30, 2026
Telix Notice of General Meeting, Proxy Form and Online Guide
Oct 29, 2026
Closed €8.09 (-4.7%) on Oct 30, 2026
Application for quotation of securities - TLX
Oct 28, 2026
Closed €8.19 (+3.4%) on Oct 28, 2026
Appendix 3Y Dr Christian Behrenbruch
Oct 26, 2026
Closed €7.92 (-0.6%) on Oct 27, 2026
Appendix 3Y William Jellison
Oct 25, 2026
Closed €7.96 (-2.1%) on Oct 26, 2026
Telix Pharmaceuticals Limited on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 102 in the last 12 months · 404 in all · newest Nov 4, 2026 · oldest 2017
- Calls
- 2 calls with a replay · 2 with a transcript · latest Aug 20, 2026
- Decks
- 63 decks · latest Nov 4, 2026
Where Telix Pharmaceuticals Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:TLX · Home listing | ASX | Australia | AUD |
| NASDAQ:TLX | NASDAQ | United States | USD |
| LS Exchange:A2H7JK | LS Exchange | Germany | EUR |
| gettex:T3X | gettex | Germany | EUR |
| Tradegate:T3X | Tradegate | Germany | EUR |
| OTC:TLPPF | OTC | United States | USD |
| BOATS:TLX | BOATS | United States | USD |
| Lang & Schwarz:A2H7JK | Lang & Schwarz | Germany | EUR |
| Frankfurt:T3X · This page | Frankfurt | Germany | EUR |
| BMV:TLX1N | BMV | Mexico | MXN |
| Dusseldorf:T3X | Dusseldorf | Germany | EUR |
| BIVA:TLX1N | BIVA | Mexico | MXN |
| Frankfurt:T3X0 | Frankfurt | Germany | EUR |
| Hamburg:T3X | Hamburg | Germany | EUR |
| Munich:T3X | Munich | Germany | EUR |
| Stuttgart:T3X | Stuttgart | Germany | EUR |
Valuation
EV/sales 4.0× against a median of 2.5×: 7th lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.87B AUD
- P/E
- Loss
- EV/sales
- 4.0×
- EV/EBITDA
- 63.0×
- Price/book
- 5.9×
- Gross margin
- 53.0%
- Operating margin
- 3.7%
- Net margin
- −0.9%
- Debt to equity
- 1.2×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Telix Pharmaceuticals Limited · ASX:TLX | US$2.90B | US$3.22B | n/a | 4.0× | 63.0× | 5.9× | −0.9% | 1.2× | n/a |
| Xeris Biopharma Holdings, Inc. · NASDAQ:XERS | US$3.10B | US$3.16B | n/a | 8.6× | 58.9× | 63.5× | −1.8% | 3.9× | 0.11 |
| Bausch Health Companies Inc. · TSX:BHC | US$3.08B | US$21.23B | n/a | 1.9× | n/a | n/a | −7.6% | n/a | 0.65 |
| Rubicon Research Limited · NSE:RUBICON | US$3.07B | US$3.05B | 98.7× | 14.6× | 62.8× | 22.1× | 14.9% | 0.1× | n/a |
| Jilin Aodong Pharmaceutical Group Co., Ltd. Class A · SZSE:000623 | US$2.98B | US$2.56B | 6.6× | 7.6× | n/a | 0.6× | 133.7% | 0.0× | n/a |
| ACADIA Pharmaceuticals Inc. · NASDAQ:ACAD | US$2.96B | US$2.05B | 8.2× | 1.7× | 15.5× | 2.1× | 30.1% | 0.1× | 0.40 |
| ADMA Biologics Inc · NASDAQ:ADMA | US$2.92B | US$2.99B | 16.0× | 5.8× | 12.0× | 6.7× | 35.1% | 0.5× | 0.05 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A · SZSE:002773 | US$2.90B | US$1.94B | 21.1× | 3.1× | n/a | 2.0× | 22.1% | 0.0× | n/a |
| China Medical System Holdings Ltd. · HKEX:867 | US$2.87B | US$2.13B | 12.8× | 1.7× | 7.7× | 1.1× | 18.1% | 0.1× | n/a |
| Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380 | US$2.80B | US$1.16B | 16.5× | 0.6× | n/a | 1.3× | 8.4% | 0.1× | n/a |
| Livzon Pharmaceutical Group, Inc. Class A · SZSE:000513 | US$2.72B | US$1.65B | 11.7× | 1.1× | n/a | 1.4× | 15.2% | 0.0× | n/a |
| Median of the others | US$2.94B | US$2.35B | 14.4× | 2.5× | 15.5× | 2.0× | 16.7% | 0.1× | 0.26 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 24.17 AUD · Analysts' mean
- EPS, year to Dec 2026
- 0.071 · 11 analysts
- Revenue, year to Dec 2026
- 1.4B · 14 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christian Behrenbruch | Managing Director & Group Chief Executive Officer |
| Darren Smith | Group Chief Financial Officer |
| Darren Patti | Group Chief Operating Officer |
| Christian Krautkramer | Group General Counsel |
| Annie Kasparian | Investor Relations |
| Charlene Jaw Associate | Director Investor Relations |
| Kyahn Williamson | SVP, Investor Relations & Corporate Communications |
| Kenneth Clarke | SVP, Global Regulatory Affairs |
| Meredith Crowe | SVP, Global People & Culture |
| Paul Schaffer | SVP, Research & Development |
| Radu Ciocan | SVP, TMS Radiopharmaceutical Operations |
| Thorsten Melcher | SVP, Global Business Development and Alliance Management |
| Tom Fromm | SVP, Corporate Sales |
| Craig Ulrick | Chief Information Officer |
| David Cade | Group Chief Medical Officer |
| Mary Jessel | Group Chief of Clinical Affairs |
Board
| Director | Role |
|---|---|
| David Gill | Chair & Independent Non-Executive Director |
| Jann Skinner | Independent Non-Executive Director |
| Maria Rivas | Independent Non-Executive Director |
| Marie McDonald | Independent Non-Executive Director |
| Mark Nelson | Independent Non-Executive Director |
| William Jellison | Independent Non-Executive Director |
Events
- Next results
- Feb 17, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 7:00 PM ET | Replay |
| Telix Pharmaceuticals (ASX:TLX) Q4 2025 Earnings Call | Thu, Aug 21, 2025 · 7:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Oct 14, 2025 | +15.3% |
| Q2 2025 | Aug 20, 2025 · Before open | −3.5% |
| Quarter to Mar 31, 2025 | Apr 22, 2025 | +10.2% |
| Q4 2024 | Feb 20, 2025 | +12.3% |
| Quarter to Sep 30, 2024 | Oct 17, 2024 | +3.4% |
| Q2 2024 | Aug 22, 2024 · After close | −3.0% |
| Q1 2024 | May 22, 2024 · Before open | +2.5% |
| Q4 2023 | Feb 22, 2024 | −4.4% |
| Quarter to Sep 30, 2023 | Oct 18, 2023 | −9.4% |
| Q2 2023 | Aug 23, 2023 · After close | +3.6% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Apr 17, 2023 · After close | +12.7% |
| Q4 2022 | Feb 27, 2023 · After close | +6.2% |
| Q3 2022 | Oct 20, 2022 · Before open | −6.7% |
| Q2 2022 | Aug 17, 2022 · After close | −8.7% |
| Q1 2022 | Jun 1, 2022 | −13.1% |
| Q4 2021 | Feb 24, 2022 · Before open | −4.5% |
| Q2 2021 | Aug 19, 2021 | +6.0% |
| Q4 2020 | Feb 25, 2021 | −2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 94 slides | Nov 4, 2026 |
| Investor Day (September 2026) | Investor day | 113 slides | Sep 22, 2026 |
| Merger or Acquisition (September 2026) | Merger or acquisition | 36 slides | Sep 21, 2026 |
| Telix Pharm — H1 2026 Earnings Presentation | Earnings | 27 slides | Aug 21, 2026 |
| William Blair Growth Conference (June 2026) | Conference | 16 slides | Jun 2, 2026 |
| Shareholder Meeting (May 2026) | Shareholder meeting | 46 slides | May 21, 2026 |
| Technical Presentation (April 2026) | Technical | 22 slides | Apr 30, 2026 |
| Investor Presentation (April 2026) | Investor deck | 20 slides | Apr 14, 2026 |
| Investor Presentation (April 2026) | Investor deck | 20 slides | Apr 14, 2026 |
| Earnings Presentation (March 2026) | Earnings | 24 slides | Mar 10, 2026 |
Show 50 decks
This page holds 50 of 63 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| At-the-market programme of new fully paid ordinary shares in the form of American Depository Shares (ADSs) Announced: Morgan Stanley & Co. LLC +1 Dealers: Morgan Stanley & Co. LLC, William Blair & Company, L.L.C. Use of proceeds: To facilitate greater access to the Company's securities on the Nasdaq stock exchange | Aug 20, 2026 |
| 1.50 per cent convertible notes due 2031 Made bigger: US$600M · J.P. Morgan Securities plc Dealers: J.P. Morgan Securities plc (lead) Use of proceeds: Refinancing of existing convertible bonds alongside a concurrent repurchase | Apr 15, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Withdrawn on Jun 14, 2024. Filed with the SEC to go public on May 17, 2024.
- ADSs offered
- 17,000,000 American depositary shares
- Listing
- TLX on the Nasdaq Global Market · Has applied to list
- Underwriters
- Jefferies, Morgan Stanley, Truist Securities, William Blair · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 25, 2024 |
| Filed publicly | May 17, 2024 |
| Amended once | Jun 5, 2024 |
| Filing withdrawn | Jun 14, 2024 |
Filings
| Filing | Filed |
|---|---|
| RW · Request to withdraw a registration | Jun 14, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 10, 2024 |
| F-1/A · Registration statement, amended | Jun 5, 2024 |
| F-1 · Registration statement | May 17, 2024 |
| DRS/A · Draft registration statement, amended | May 9, 2024 |
| DRS/A · Draft registration statement, amended | Apr 15, 2024 |
| DRS/A · Draft registration statement, amended | Mar 15, 2024 |
| DRS/A · Draft registration statement, amended | Feb 2, 2024 |
| DRS · Draft registration statement | Jan 25, 2024 |
Open IPO · From the cover of the amended prospectus (F-1/A) filed Jun 5, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 803.8M | 516.6M | 333.0M | 160.1M | 7.60M | 5.21M | 3.48M | 195.1K | 403.5K | 0 |
| Cost of revenue | 377.4M | 180.4M | 123.4M | 130.8M | 37.4M | 2.02M | 15.4M | 0 | 3.79K | 0 |
| Gross profit | 426.4M | 336.2M | 209.5M | 29.3M | -29.8M | 3.19M | -11.9M | 195.1K | -3.79K | 0 |
| Research and development | 171.2M | 127.9M | 85.3M | 57.9M | 34.1M | 23.1M | 21.2M | 18.7M | 2.98M | 10.0K |
| Selling, general and administrative | 94.0M | 49.1M | 41.1M | 18.0M | 11.3M | 8.50M | 2.46M | 20.0K | ||
| Operating income | 29.8M | 55.2M | 11.0M | -73.2M | -81.2M | -49.3M | -40.3M | -27.6M | -6.52M | -30.0K |
| Depreciation and amortization | 21.4M | 5.28M | 4.16M | 5.38M | 5.17M | 4.88M | 4.24M | 6.97K | 3.79K | 30.0K |
| EBITDA | 51.2M | 60.5M | 15.2M | -67.8M | -76.1M | -44.4M | -36.0M | -27.6M | -6.52M | 0 |
| Interest expense | 181.0K | 64.0K | 97.0K | 406.0K | 189.0K | 1.18M | 2.41M | 29.0K | 9.40K | 0 |
| Income before tax | -5.27M | 37.9M | 2.59M | -98.6M | -99.0M | -60.3M | -42.8M | -15.7M | -6.38M | -44.0K |
| Income tax | 1.86M | 4.23M | -1.61M | 5.46M | -18.5M | -15.4M | -14.9M | -1.88M | -403.5K | -14.0K |
| Net income | -7.13M | 33.7M | 4.21M | -104.1M | -80.5M | -44.9M | -27.9M | -13.8M | -6.38M | -44.0K |
| Earnings per share, basic | -0.02 | 0.10 | 0.01 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | -0.00 |
| Earnings per share, diluted | -0.02 | 0.10 | 0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 141.9M | 440.0M | 84.3M | 116.3M | 22.0M | 77.9M | 44.6M | 25.8M | 48.8M | |
| Receivables | 129.2M | 86.9M | 44.0M | 45.9M | 20.8M | 14.2M | 13.0M | 8.44M | 488.8K | |
| Inventory | 37.1M | 23.6M | 12.7M | 8.48M | 3.45M | 633.0K | 542.0K | 642.5K | 297.2K | |
| Current assets | 330.3M | 570.1M | 158.7M | 173.2M | 47.5M | 93.6M | 58.7M | 35.9M | 49.5M | |
| Property, plant and equipment | 58.7M | 27.8M | 15.8M | 18.8M | 6.33M | 4.82M | 1.90M | 226.0K | 5.39K | |
| Goodwill | 199.0M | 66.6M | 5.52M | 4.10M | 4.22M | 4.22M | 3.14M | 332.5K | ||
| Total assets | 1.16B | 940.4M | 277.3M | 255.4M | 109.8M | 157.8M | 102.6M | 76.7M | 51.1M | |
| Accounts payable | 150.3M | 86.8M | 54.3M | 16.8M | 11.9M | 5.81M | 6.96M | 3.25M | 275.8K | |
| Current liabilities | 231.6M | 205.1M | 111.4M | 85.6M | 38.0M | 20.0M | 10.6M | 8.24M | 1.47M | |
| Long-term debt | 391.9M | 341.8M | 5.95M | 3.31M | 0 | 95.0K | 292.0K | 596.3K | ||
| Total debt | 405.0M | 353.6M | 6.61M | 10.4M | 2.54M | 2.21M | 2.13M | 1.73M | 345.4K | |
| Total liabilities | 748.6M | 587.4M | 174.6M | 175.3M | 106.2M | 78.8M | 32.5M | 23.8M | 1.80M | |
| Shareholders' equity | 415.4M | 352.9M | 102.6M | 80.0M | 2.16M | 79.0M | 70.1M | 52.9M | 49.3M | |
| Shares outstanding | 337.9M | 310.6M | 282.2M | 257.3M | 233.4M | 202.1M | 128.0M | 128.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -17.3M | 27.5M | 14.3M | -64.0M | -59.3M | 1.96M | -23.3M | -20.7M | -6.03M | -6.03M |
| Capital spending | -25.7M | -9.12M | -6.31M | -13.9M | -1.34M | -322.0K | -468.0K | -403.0K | -5.64K | -5.64K |
| Free cash flow | -43.0M | 18.4M | 7.97M | -77.8M | -60.7M | 1.64M | -23.8M | -20.7M | -6.04M | -6.04M |
| Cash from investing | -285.9M | -86.7M | -16.8M | -17.0M | -2.73M | -1.09M | -468.0K | -2.69M | -1.26K | -1.26K |
| Cash from financing | -3.72M | 416.8M | 7.09M | 175.0M | 2.85M | 34.1M | 42.7M | -869.4K | 54.8M | 54.8M |
| Dividends paid | -168.4M | -34.5M | -54.8M | |||||||
| Share buybacks | 1.81M | -7.82M | 3.78M | -130.0K | 45.3M | 0 | -2.99M | 58.6M | ||
| Change in cash | -306.9M | 357.6M | 4.53M | 94.3M | -55.9M | 33.3M | 18.8M | -23.0M | 54.8M | 48.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Appendix 3Y Maria Rivas | Nov 4, 2026 | Other filings | ASX |
| Telix Capital Markets Day Presentation November 2026 | Nov 3, 2026 | Other filings | ASX |
| Change of Director's Interest Notice - Marie McDonald | Nov 3, 2026 | Ownership change notice | ASX |
| Notification regarding unquoted securities - TLX | Nov 3, 2026 | Other filings | ASX |
| Cancellation of Appendix 2A | Nov 2, 2026 | Financing | ASX |
| Telix Notice of General Meeting, Proxy Form and Online Guide | Oct 29, 2026 | Meeting notice | ASX |
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
| Application for quotation of securities - TLX | Oct 28, 2026 | Financing | ASX |
| Appendix 3Y Dr Christian Behrenbruch | Oct 26, 2026 | Other filings | ASX |
| Appendix 3Y William Jellison | Oct 25, 2026 | Other filings | ASX |
Show 200 filings
This page holds 200 of 441 filings. Open Filings
Cap table
Built by 6ix from Telix Pharmaceuticals Limited’s releases · as of Aug 20, 2026
- Common shares
- 338,777,049
- Fully diluted
- 338,777,049
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 338,777,049 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 338,777,049 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Gill Other companies: Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past) | Chair & Independent Non-Executive Director · Since Apr 2, 2026 |
| William Jellison Other companies: Medtronic plc. (Director · Since at least Aug 19, 2025); Masimo Corporation (Director · Since at least Sep 19, 2024); Anika Therapeutics Inc. (Director · Since at least May 28, 2024); Avient Corporation (Director · Since at least Oct 7, 2015); Stryker Corporation (VP and CFO · Apr 22, 2013 – Feb 11, 2015 · Past); Dentsply Sirona Inc. (Sr. VP & C.F.O. · Feb 13, 2006 – Apr 12, 2013 · Past) | Independent Non-Executive Director · Since at least May 11, 2026 |
| Maria Rivas Other companies: The Cooper Companies, Inc. (Director · Since at least Jul 1, 2021); Medidata Solutions Inc (Director · Oct 19, 2018 – Oct 28, 2019 · Past) | Independent Non-Executive Director · Since at least May 11, 2026 |
| Annie Kasparian | Investor Relations · Since at least Sep 1, 2026 |
| Charlene Jaw Associate | Director Investor Relations · Since at least Jun 23, 2026 |
| Christian Behrenbruch | Managing Director & Group Chief Executive Officer · Since at least Mar 18, 2026 |
| Christian Krautkramer | Group General Counsel · Since at least Nov 5, 2026 |
| Craig Ulrick | Chief Information Officer · Since at least Nov 5, 2026 |
| Darren Patti | Group Chief Operating Officer · Since at least Jun 4, 2025 |
| Darren Smith | Group Chief Financial Officer · Since at least Mar 18, 2026 |
All 25 people
| Person | Seat |
|---|---|
| David Cade | Group Chief Medical Officer · Since at least Mar 18, 2026 |
| Jann Skinner | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Kenneth Clarke | SVP, Global Regulatory Affairs · Since at least Nov 5, 2026 |
| Kevin Richardson | Telix Precision Medicine · Until May 6, 2026 · Past |
| Kyahn Williamson | SVP, Investor Relations & Corporate Communications · Since at least Jun 23, 2026 |
| Marie McDonald | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Mark Nelson | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Mary Jessel | Group Chief of Clinical Affairs · Since at least May 20, 2025 |
| Meredith Crowe | SVP, Global People & Culture · Since at least Nov 5, 2026 |
| Paul Schaffer | SVP, Research & Development · Since at least Nov 5, 2026 |
| Radu Ciocan | SVP, TMS Radiopharmaceutical Operations · Since at least Nov 5, 2026 |
| Raphaël Ortiz | Telix International · May 1, 2026 – May 6, 2026 · Past |
| Richard Valeix | Telix Therapeutics · Until May 6, 2026 · Past |
| Thorsten Melcher | SVP, Global Business Development and Alliance Management · Since at least Nov 5, 2026 |
| Tom Fromm | SVP, Corporate Sales · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Telix Pharmaceuticals Limited.